View Older Stories View More Recent Stories
-
Lumos Pharma to Participate in Upcoming Investor Conferences
-
Endologix Names Dr. Matthew Thompson President and CEO
-
Biotech Acquisition (BIOT) and Blade Therapeutics Announce Definitive Merger Agreement
-
Biotech Acquisition Company and Blade Therapeutics Announce Definitive Merger Agreement
-
Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates
-
Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates
-
Second Annual $500,000 XSeed Award Launched by Deerfield Management to Support Underfunded and Underrepresented NYC Life Science Startups
-
DFP Healthcare Acquisitions (DFPH) Schedules Special Meeting to Approve Proposed Merger with The Oncology Institute for November 12th
-
DFP Healthcare Acquisitions Corp. Announces Special Meeting Date to Approve Proposed Business Combination with The Oncology Institute
-
Form 3 Xilio Therapeutics, Inc. For: Oct 21 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
-
Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
-
Lark Health Raises $100 Million Series D Funding Round Led by Deerfield Management
-
DeepSight™ Technology Announces $25M Series A Funding Round
-
Caring Cross Presents at the 2021 BioFuture Conference
-
Salarius Pharmaceuticals to Present at the 2021 BioFuture Conference
-
BioAtla (BCAB) Announces Private Placement of 2.7 Million Shares
-
BioAtla Announces Private Placement of 2.7 Million Shares
-
Endologix Initiates Randomized Study of ALTO® Abdominal Stent Graft System
-
Amicus Therapeutics (FOLD) and ARYA Sciences Acquisition Corp IV (ARYD) Announce Formation of a Next-Generation Genetic Medicine Company: “Caritas Therapeutics”
-
Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: “Caritas Therapeutics”
-
The New York Academy of Medicine to Honor Innovators in Health with Remarks from Dr. Anthony Fauci
-
Behavioral Health Leader Christina Mainelli Joins Quartet Health to Accelerate Strategic Growth
-
Vincerx Pharma, Inc (VINC) Announces 3.5M Share Private Placement at $14.50
-
Vincerx Pharma Announces $50 Million Private Placement
-
Dr. Patrice Harris Joins Quartet Health's Board of Directors
-
iECURE Launches With $50 Million Series A Financing to Develop In Vivo Gene Insertion Approaches for Devastating Diseases
-
HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate
-
Demy-Colton Announces BioFuture™ Speaker Lineup and Panel Sessions on October 5-6 at Cure by Deerfield in New York City
-
Form 4 Acutus Medical, Inc. For: Jun 17 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Civetta Therapeutics Announces the Appointment of Christopher D. Roberts, Ph.D., as CEO
-
Lumos Pharma to Participate in September Investor Conferences
-
Lumos Pharma to Participate in September Investor Conferences
-
ARS Pharmaceuticals Raises $55 Million in Series D Funding for Launch Preparations of Neffy™ (epinephrine nasal spray)
-
The Cure Commences Fall Session of the Cure Symposia as Part of Its In-House Educational Programming
-
Blade Therapeutics Announces FDA Activation of IND Application to Investigate Cudetaxestat, a Non-Competitive Autotaxin Inhibitor, in Idiopathic Pulmonary Fibrosis (IPF)
-
Form 13F-HR DEERFIELD MANAGEMENT For: Jun 30
-
Form SC 13D DA32 Life Science Tech Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Form 4 DA32 Life Science Tech For: Aug 05 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Miravo Healthcare™ Announces Second Quarter 2021 Results
-
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
-
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
-
PepGen Announces Closing of $112.5 Million Crossover Financing to Advance Transformative Therapies for Neuromuscular Diseases
-
Deerfield Announces New $1.4-billion Private Investment Fund
-
Form 4 DA32 Life Science Tech For: Jul 30 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Lumos Pharma, Inc. (LUMO) Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer
-
Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer
-
Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer
-
Lumos Pharma, Inc. (LUMO) Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President
-
Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President

